| | | April 29, 2022 Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. Happy Friday! It's April 29th. Let's get ready to trade! |
The Nasdaq rallied 3.1% on Thursday as US stocks rallied back after several days of losses. The S&P 500 gained 2.5% on the session, and the Dow added 1.9% while the Russell 2K small-cap index jumped 1.8%. Futures are pointing to a lower open after a weak earnings report from Amazon sparked widespread selling. S&P 500 contracts are currently showing a 0.9% loss. Mohawk Industries [MHK] - Last Close: $130.78 Mohawk Industries is surging on a strong quarterly report. The flooring products manufacturer reported better-than-expected Q1 adjusted earnings of $3.78 on revenues of $3.0 billion, marking sales growth of 13%. Analysts expected EPS of $2.90 on revenues of $2.85 billion. Mohawk's Q2 forecast of $4.25 to $4.35 per share beat the Street's view of $3.75 by a wide margin.
MHK is leading the S&P 500 with an 11.6% gain. Alibaba ADR [BABA] - Last Close: $90.91
New commitments from Chinese leaders is rallying shares of Alibaba. The Chinese Communist Party's Politburo pledged to support the healthy growth of the tech industry, and top leaders have implied that they will take drastic action to support China's growth amid its ongoing COVID outbreak. American investors speculate that the pivot could be a sign that the Chinese government's crackdown on its tech sector may be coming to a close. BABA is one of the top-performing Chinese tech stocks in today's premarket. The stock is up 11.2% on active trading volume. Zymeworks Inc [ZYME] - Last Close: $4.96
Zymeworks is surging on news of a potential buyout deal. The company confirmed on Thursday that it had received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to buy the company for $10.50 per share in cash. Zymeworks' board will review the proposal and announce their decision soon. ZYME is trading actively with a 43.8% gain. Finch Therapeutics Group [FNCH] - Last Close: $2.10 A positive regulatory decision is rallying Finch Therapeutics. The microbiome therapeutics company said late Thursday that regulators at the US Food and Drug Administration have removed its clinical hold on its investigational new drug application for its CP101 drug candidate for the prevention of recurrent C. difficile infection. FDA lifted its hold after reviewing information Finch provided to regulators regarding its COVID-19 screening procedures and associated informed consent language. Finch plans to proceed with enrollment in the late-stage PRISM4 trial soon. FNCH is trading actively with a 56.2% gain. |
| Gainers Fangdd Network [DUO] >> +73.7% Didi Global [DIDI] >> +14.4% Field Trip Health [FTRP] >> +20.0% Decliners Stratera Biopharma [STAB] >> (18.4%) Accolade Inc [ACCD] >> (38.4%) Genocea Biosciences [GNCA] >> (36.3%) ExxonMobil [XOM] ... AM Chevron [CVX] ... AM AbbVie [ABBV] ... AM AstraZeneca [AZN] ... AM Honeywell Intl. [HON] ... AM Charter Communications [CHTR] ... AM Aon [AON] ... AM Colgate Palmolive [CL] ... AM Phillips 66 [PSX] ... PM CBOE Global Markets [CBOE] ... AM Syneos Health [SYNH] ... AM |
| Consumer Spending [Mar] ... 8:30a UMich Consumer Sentiment [Apr] ... 10a |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
